H.Pylori Infection
18
3
3
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
28%
5 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (18)
Tegoprazan and Amoxicillin Dual Therapy
RUT vs. Molecular Testing for H. Pylori
Tegoprazan- Versus PPI-based H. Pylori Eradication
CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication
Barriers of General Practitioner Regarding Helicobacter Pylori.
Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection
Comparison of Twice- and Four-times-daily Amoxicillin Administration in 2-week Tegoprazan-based H. Pylori Eradication
Intrafamilial Helicobacter Pylori Infection in Hong Kong
Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians
Relation of Helicobacter Pylori in Prediabetic Patients
Frequency of h.Pylori in Children With Dyspeptic Symptoms
Prevalence of H.Pylori in CKD Patients
Concomitant Versus Hybrid Regimen for H. Pylori Eradication
Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach
h.Pylori Ttt With Rebamipide
Comparative Anti Helicobacter Pylori Efficacy Assessment of Unani Formulation and Quintuple Regimen
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication
Volatile Markers in Digestive Cancer